Answers are grounded in this paper and cite their sources.
BACKGROUND: A family history of autoimmune disease (AIDFH) is noted in patients with antiphospholipid syndrome (APS), yet its clinical significance remains underexplored. This study aims to assess the impact of AIDFH on clinical and immunological features of individuals with persistent antiphospholipid antibody (aPL) positivity. METHODS: Data were drawn from the Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks (CAPSTONE), the first prospective, multicenter cohort of participants with confirmed persistent aPL positivity in China. Patients from five CAPSTONE sites (Oct 2022-Oct 2024) were stratified by AIDFH status. Demographic, clinical, and serological parameters were compared. Whole-exome sequencing (WES) was performed, and human leukocyte antigen (HLA) alleles were analyzed. RESULTS: Among 936 patients, 72 (7.7%) reported AIDFH. These patients had earlier disease onset (27.6 years vs. 29.8 years, P = 0.027), more overlap with systemic lupus erythematosus (SLE) (43.1% [31/72] vs. 29.4% [254/864], P = 0.016), and higher antinuclear antibody (ANA) positivity (73.9% [51/69] vs. 55.1% [441/801], P = 0.002). In those meeting the 2006 revised Sydney classification criteria for APS, AIDFH correlated with lower frequency of primary APS, and increased rates of pulmonary embolism, chronic thromboembolic pulmonary hypertension, valve thickening, and various ANAs. Subgroup analysis showed that family history of SLE was linked to more SLE overlap, and elevated ANA, anti-dsDNA, anti-ribosomal ribonucleoprotein antibody (anti-rRNP), and Coomb's positivity. Among 374 patients with WES data, HLA-DRB1*08:02 was significantly more frequently shown in AIDFH-positive patients (P = 9.3 × 10-5). CONCLUSION: Our cohort shows that in patients with persistent aPL positivity, those with AIDFH may have unique clinical and immunogenetic backgrounds. This study provides preliminary evidence for further studies focusing on genetic predisposition and mechanisms. We call for raised attention of AIDFH as a potential risk factor, and further studies are needed to provide suggestions on prognosis and overall management of patients with persistent aPL positivity.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: